TY - JOUR
T1 - Systematic Review with Meta-Analysis
T2 - Fecal Microbiota Transplantation for Severe or Fulminant Clostridioides difficile
AU - Tixier, Emily N.
AU - Verheyen, Elijah
AU - Luo, Yuying
AU - Grinspan, Lauren Tal
AU - Du, Charles H.
AU - Ungaro, Ryan C.
AU - Walsh, Samantha
AU - Grinspan, Ari M.
N1 - Publisher Copyright:
© 2021, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
PY - 2022/3
Y1 - 2022/3
N2 - Background: Severe and fulminant Clostridioides difficile infection (CDI) is associated with significant morbidity and mortality. While fecal microbiota transplantation (FMT) has proved to be a highly effective treatment for recurrent CDI, its efficacy in severe or fulminant CDI remains uncertain. Aims: To perform a systematic review with meta-analysis evaluating clinical outcomes and safety of FMT in severe and fulminant CDI. Methods: A systemic review with meta-analysis was performed through comprehensive search of Embase, Medline (Ovid), trial registers, and conference abstracts through January 2020. Studies on FMT in severe and fulminant CDI were included. Meta-analysis was done with random effects models given heterogeneity to estimate rates of cure, mortality, and colectomy. Publication bias was assessed using Egger’s test. Results: Sixteen studies comprised of one randomized controlled trial, four cohort studies, and eleven case series were analyzed. In total, 676 patients underwent FMT for severe or fulminant CDI. The overall rate of clinical cure after single FMT was 61.3% (95% CI 43.2–78.0%) with 10.9% (95% CI 0.2–30.2%) of patients experiencing major adverse events. The overall pooled colectomy rate after FMT was 8.2% (95% CI 0.1–23.7%) with a pooled all-cause mortality rate after FMT of 15.6% (95% CI 7.8–25.0%). Conclusion: Low-quality data support the use of fecal microbiota transplantation in patients with severe and fulminant Clostridioides difficile infection.
AB - Background: Severe and fulminant Clostridioides difficile infection (CDI) is associated with significant morbidity and mortality. While fecal microbiota transplantation (FMT) has proved to be a highly effective treatment for recurrent CDI, its efficacy in severe or fulminant CDI remains uncertain. Aims: To perform a systematic review with meta-analysis evaluating clinical outcomes and safety of FMT in severe and fulminant CDI. Methods: A systemic review with meta-analysis was performed through comprehensive search of Embase, Medline (Ovid), trial registers, and conference abstracts through January 2020. Studies on FMT in severe and fulminant CDI were included. Meta-analysis was done with random effects models given heterogeneity to estimate rates of cure, mortality, and colectomy. Publication bias was assessed using Egger’s test. Results: Sixteen studies comprised of one randomized controlled trial, four cohort studies, and eleven case series were analyzed. In total, 676 patients underwent FMT for severe or fulminant CDI. The overall rate of clinical cure after single FMT was 61.3% (95% CI 43.2–78.0%) with 10.9% (95% CI 0.2–30.2%) of patients experiencing major adverse events. The overall pooled colectomy rate after FMT was 8.2% (95% CI 0.1–23.7%) with a pooled all-cause mortality rate after FMT of 15.6% (95% CI 7.8–25.0%). Conclusion: Low-quality data support the use of fecal microbiota transplantation in patients with severe and fulminant Clostridioides difficile infection.
KW - CDI
KW - Clostridioides difficile
KW - Clostridium difficile
KW - FMT
KW - Fecal microbiota transplantation
UR - http://www.scopus.com/inward/record.url?scp=85103178917&partnerID=8YFLogxK
U2 - 10.1007/s10620-021-06908-4
DO - 10.1007/s10620-021-06908-4
M3 - Article
C2 - 33748913
AN - SCOPUS:85103178917
SN - 0163-2116
VL - 67
SP - 978
EP - 988
JO - Digestive Diseases and Sciences
JF - Digestive Diseases and Sciences
IS - 3
ER -